Evidence map›Paper›PMID 42095505›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Rewiring NADH Metabolism Through NQO1-Mediated Redox Cycling for Targeted Follicular Lymphoma Therapy.

Jinxing Zhang, Ziqi Wang, Ye Weng, Yulin Fu, Yuelong Jiang, Beilin Zhuang, Wenzi Zeng, Xiangchun Zhang, Bing Xu, Jie Zha and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jinxing ZhangDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Ziqi WangState Key Laboratory of Tea Plant Germplasm Innovation and Resource Utilization, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, China.
Ye WengDepartment of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yulin FuDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Yuelong JiangDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Beilin ZhuangDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Wenzi ZengDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Xiangchun ZhangState Key Laboratory of Tea Plant Germplasm Innovation and Resource Utilization, Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou, China.ORCID https://orcid.org/0000-0001-9292-3563
Bing XuDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.ORCID https://orcid.org/0000-0003-4273-5462
Jie ZhaDepartment of Hematology, School of Medicine, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, Xiamen, China.
Hongjun ZhuangDepartment of Rheumatology and Clinical Immunology, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.ORCID https://orcid.org/0000-0003-0598-1736

Funding

Chinese Academy of Agricultural Sciences CAASASTIP-2021-TRIFujian Provincial Health and Medical Young and Middle-aged Talents Overseas (Abroad) Research and Study ProgramMedical-Engineering Integrated Guiding Project of Xiamen Science and Technology Bureau 3502Z20244ZD2007National Health Commission Capacity Building and Continuing Education Center GWJJMB202510025080National Natural Science Foundation of China 32372757National Natural Science Foundation of China 82170180National Natural Science Foundation of China 82202326National Natural Science Foundation of China 82470187National Natural Science Foundation of China U22A2090Natural Science Foundation of Fujian Province 2023J06054Xiamen Municipal Bureau of Science and Technology 3502Z20234001Xiamen Municipal Bureau of Science and Technology 3502Z20244015Xiamen Public Hospital High Quality Development Project XDFY-AW-2406-003Xiamen Public Hospital High Quality Development Project XYP2023001
6 · The paper itself

Abstract

Follicular lymphoma (FL) remains an incurable B-cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating quinone-based chemotherapeutics. To overcome this, we developed a novel therapeutic strategy that simultaneously upregulates NQO1 expression and provides its quinone substrate within tumor cells. This approach leverages the dual biological function of Cu

Indexed as

CatechinLymphoma, FollicularNADNAD(P)H Dehydrogenase (Quinone)AnimalsCell Line, TumorCopperHumansMiceOxidation-ReductionCatechinCopperepigallocatechin gallateNADNAD(P)H Dehydrogenase (Quinone)NQO1 protein, humancopper ionepigallocatechin gallatefollicular lymphomaNAD(P)H: quinone oxidoreductase 1redox cycling

Identifiers

PMID42095505
PMCPMC13335828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.